234 related articles for article (PubMed ID: 31373223)
1. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer.
Li A; He K; Guo D; Liu C; Wang D; Mu X; Yu J
Future Oncol; 2019 Oct; 15(28):3233-3242. PubMed ID: 31373223
[No Abstract] [Full Text] [Related]
2. Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
Huang D; Lin Q; Song J; Xu B
Dig Surg; 2021; 38(1):24-29. PubMed ID: 33171467
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer.
Cheong C; Shin JS; Suh KW
World J Gastroenterol; 2020 Nov; 26(44):7022-7035. PubMed ID: 33311947
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Mohri Y; Kusunoki M
Anticancer Res; 2013 Nov; 33(11):5065-74. PubMed ID: 24222151
[TBL] [Abstract][Full Text] [Related]
5. Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Lee JH; Song C; Kang SB; Lee HS; Lee KW; Kim JS
Anticancer Res; 2018 Dec; 38(12):6905-6910. PubMed ID: 30504408
[TBL] [Abstract][Full Text] [Related]
6. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.
Clarke TL; White DA; Osborne ME; Shaw AM; Smart NJ; Daniels IR
Ann R Coll Surg Engl; 2017 May; 99(5):373-377. PubMed ID: 28462648
[TBL] [Abstract][Full Text] [Related]
7. Analyses of predictive factors for pathological complete remission in neoadjuvant therapy for locally advanced rectal cancer.
Yang J; Ling X; Tang W; Hu D; Zhou H; Yin G
J BUON; 2019; 24(1):77-83. PubMed ID: 30941954
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.
Yeo SG; Kim DY; Chang HJ; Park JW; Oh JH; Kim BC; Baek JY; Kim SY; Kim TH
Tumori; 2013; 99(1):93-9. PubMed ID: 23549007
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
[TBL] [Abstract][Full Text] [Related]
10. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
Kitayama J; Yasuda K; Kawai K; Sunami E; Nagawa H
Radiat Oncol; 2010 Jun; 5():47. PubMed ID: 20525293
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.
Tada N; Kawai K; Tsuno NH; Ishihara S; Yamaguchi H; Sunami E; Kitayama J; Oba K; Watanabe T
World J Surg Oncol; 2015 Feb; 13():30. PubMed ID: 25890185
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.
Yang KL; Yang SH; Liang WY; Kuo YJ; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Chu LS; Wang LW
Radiat Oncol; 2013 Mar; 8():43. PubMed ID: 23452434
[TBL] [Abstract][Full Text] [Related]
13. Can pretreatment blood biomarkers predict pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer?
Morais M; Fonseca T; Machado-Neves R; Honavar M; Coelho AR; Lopes J; Barbosa E; Guerreiro E; Carneiro S
Future Oncol; 2021 Dec; 17(35):4947-4957. PubMed ID: 34734533
[No Abstract] [Full Text] [Related]
14. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?
Braun LH; Baumann D; Zwirner K; Eipper E; Hauth F; Peter A; Zips D; Gani C
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108935
[TBL] [Abstract][Full Text] [Related]
16. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma.
Yan H; Wang R; Zhu K; Zhao W; Jiang S; Feng R; Xu X; Meng X; Sun H; Zhang H; Mu D; Xu Z
Tumori; 2011; 97(6):717-23. PubMed ID: 22322837
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Kim CW; Yu CS; Yang SS; Kim KH; Yoon YS; Yoon SN; Lim SB; Kim JC
Ann Surg Oncol; 2011 Nov; 18(12):3271-7. PubMed ID: 21537868
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.
Song S; Hong JC; McDonnell SE; Koong AC; Minsky BD; Chang DT; Liauw SL
Ann Surg Oncol; 2012 Aug; 19(8):2471-6. PubMed ID: 22327251
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Leukocyte- and Platelet-Derived Ratios in Rectal Adenocarcinoma.
Ward WH; Goel N; Ruth KJ; Esposito AC; Lambreton F; Sigurdson ER; Meyer JE; Farma JM
J Surg Res; 2018 Dec; 232():275-282. PubMed ID: 30463730
[TBL] [Abstract][Full Text] [Related]
20. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
